[go: up one dir, main page]

NO20090053L - Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer - Google Patents

Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Info

Publication number
NO20090053L
NO20090053L NO20090053A NO20090053A NO20090053L NO 20090053 L NO20090053 L NO 20090053L NO 20090053 A NO20090053 A NO 20090053A NO 20090053 A NO20090053 A NO 20090053A NO 20090053 L NO20090053 L NO 20090053L
Authority
NO
Norway
Prior art keywords
cancer
treatment
methods
tak1 inhibitors
tak1
Prior art date
Application number
NO20090053A
Other languages
English (en)
Inventor
Kate Byth
Sangeetha Palakurthi
Lihua Yu
Qi Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090053L publication Critical patent/NO20090053L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives, til dels, en fremgangsmåte for å inhibere lymfoid tumorcelleproliferasjon ved å bringe lymfoidet i kontakt med en TAK1-inhibitor.
NO20090053A 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer NO20090053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80684506P 2006-07-10 2006-07-10
PCT/GB2007/002568 WO2008007072A2 (en) 2006-07-10 2007-07-10 Methods for cancer treatment using tak1 inhibitors

Publications (1)

Publication Number Publication Date
NO20090053L true NO20090053L (no) 2009-02-06

Family

ID=38920633

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090053A NO20090053L (no) 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Country Status (12)

Country Link
US (1) US20090312396A1 (no)
EP (1) EP2041303A2 (no)
JP (1) JP2009544583A (no)
KR (1) KR20090027735A (no)
CN (1) CN101490279A (no)
AU (1) AU2007274055A1 (no)
BR (1) BRPI0714158A2 (no)
CA (1) CA2658163A1 (no)
IL (1) IL196208A0 (no)
MX (1) MX2009000376A (no)
NO (1) NO20090053L (no)
WO (1) WO2008007072A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101559B2 (en) * 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
CN101968491A (zh) * 2010-09-29 2011-02-09 上海生物芯片有限公司 弥漫性大b细胞淋巴瘤分子病理分型方法及试剂盒和应用
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
US20140243403A1 (en) * 2011-06-03 2014-08-28 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
WO2013012998A1 (en) 2011-07-19 2013-01-24 Emory University Tak1 kinase inhibitors, compositions, and used related thereto
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2932351A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6788583B2 (ja) 2014-10-22 2020-11-25 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 増殖性疾患を処置するためのチアゾリル含有化合物
CN104911183B (zh) * 2015-06-25 2018-01-09 中山大学孙逸仙纪念医院 抑制胰腺癌TAK1基因表达的shRNA的转录模板
WO2018060452A1 (en) * 2016-09-30 2018-04-05 Fundació Institut Mar D'investigacions Mèdiques (Imim) Therapeutic approaches to cancer
CN109420170B (zh) 2017-08-25 2021-03-02 中国科学院上海营养与健康研究所 肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用
EP4464318A1 (en) * 2023-05-19 2024-11-20 Albert-Ludwigs-Universität Freiburg Targeting tgf-b-activated kinase-1 activation in the treatment of neuroinflammatory conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025362A1 (de) * 2004-05-19 2005-12-22 Sanofi-Aventis Deutschland Gmbh Verwendung der TGFbeta-aktivierten Kinase 1
WO2006023210A2 (en) * 2004-07-23 2006-03-02 Aveo Pharmaceuticals, Inc. Gp132: mehods and compositions for treating cancer
WO2007044571A2 (en) * 2005-10-06 2007-04-19 President And Fellows Of Harvard College Methods for identifying proteins essential for human cell proliferation and therapeutic agents that target them

Also Published As

Publication number Publication date
AU2007274055A1 (en) 2008-01-17
BRPI0714158A2 (pt) 2012-12-25
US20090312396A1 (en) 2009-12-17
WO2008007072A3 (en) 2008-05-08
JP2009544583A (ja) 2009-12-17
WO2008007072A8 (en) 2009-02-26
IL196208A0 (en) 2009-09-22
CN101490279A (zh) 2009-07-22
KR20090027735A (ko) 2009-03-17
EP2041303A2 (en) 2009-04-01
CA2658163A1 (en) 2008-01-17
MX2009000376A (es) 2009-03-09
WO2008007072A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
NO20090053L (no) Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
ATE499102T1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EP2331530B8 (en) Fused multicyclic compounds as protein kinase inhibitors
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
WO2009134658A3 (en) Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
IN2012DN03012A (no)
MY147832A (en) Compounds for enzyme inhibition
NO20082683L (no) Neuroendokrin tumorbehandling
GEP20135957B (en) Heterocyclic compound and usage thereof
WO2008031820A3 (en) Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
MX2010005395A (es) Metodo para tratar artritis.
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
WO2006055635A3 (en) Compositions and methods for altering wnt autocrine signaling
EA201101041A1 (ru) Производные пиридазинона
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
EA201001576A1 (ru) Тиенопиримидины
NZ593849A (en) Methods to treat cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application